Scarica l'app Stockscreener
2.24
7.69%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break - Bez Kabli
Adial Pharmaceuticals (ADIL) Drops 9.57% as Selling Pressure Mounts Near Key SupportShakeout Pattern - Newser
ADIL Q1 2026 Earnings: Narrowed Loss Beats Estimates, but Market Remains CautiousSocial Flow Trades - Newser
ADIL Q1 2026 Earnings: Narrowing Loss Beats Estimates, But Stock Declines Amid No RevenuePost-Earnings Reaction - Newser
Adial Pharmaceuticals lead drug fits new policy mood as bipartisan bill signals broader lens on alcohol use disorder - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is Adial Pharmaceuticals, Inc. (ADIL) Stock Down Today? - Meyka
Why Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) Stock Up Today? - Meyka
Armistice Capital/Steven Boyd report 4.99% stake in Adial (NASDAQ: ADIL) - Stock Titan
ADIL Should I Buy - Intellectia AI
Maxim Group Maintains Adial Pharmaceuticals(ADIL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Adial Pharmaceuticals 1Q Loss $2M >ADIL - Moomoo
The quiet strength in Adial Pharma (ADIL) business model (+4.20%) 2026-05-11Community Chart Signals - Newser
Adial Pharmaceuticals: Runway to Fund Operating Expenses Into 2nd Half of 2026 >ADIL - Moomoo
Adial Pharmaceuticals Q1 Net Income USD2 Million - TradingView
Adial Pharmaceuticals Reports Q1 2026 Results, Advances AD04 for Alcohol Use Disorder with FDA and European Developments 12 - Minichart
Adial Pharmaceuticals (NASDAQ: ADIL) details evolving AD04 development and IP - Stock Titan
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update - ChartMill
Adial Pharmaceuticals Q1 2026 10-Q Report: Clinical Development of AD04 for Alcohol Use Disorder, Financial Results, and Liquidity Update - Minichart
Adial Pharmaceuticals Inc (ADIL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Adial Pharmaceuticals Inc expected to post a loss of $1.21 a shareEarnings Preview - TradingView
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Adial (NASDAQ: ADIL) flags going concern risk while advancing AD04 partnership plans - Stock Titan
ADIL Price Today: Adial Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
The quiet positioning of Adial Pharma (ADIL) nobody discusses (-10.13%) 2026-05-08Value ETF - Newser
EBIT per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
ADIL Stock Price, Quote & Chart | ADIAL PHARMACEUTICALS INC (NASDAQ:ADIL) - ChartMill
Adial Pharmaceuticals files patent application for AD04 By Investing.com - Investing.com South Africa
Adial Pharmaceuticals files patent application for AD04 - Investing.com
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 - The Manila Times
Adial seeks U.S. patent that could protect its lead alcohol-use drug to 2045 - Stock Titan
Adial Pharmaceuticals Files New U.S. Utility Patent Application For AD04 Targeting Alcohol Use Disorder - marketscreener.com
Exclusive: Adial Pharmaceuticals clears manufacturing milestone ahead of pivotal study for alcohol use disorder drug - MSN
Why did Adial Pharmaceuticals stock plunge over 20% after hours today? - MSN
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals (ADIL) Submits Application to FDA's National Priority Voucher Program - GuruFocus
Adial Pharmaceuticals applies for FDA priority voucher program - Investing.com
Adial Pharmaceuticals applies for FDA priority voucher program By Investing.com - Investing.com India
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program - The Manila Times
Adial Pharmaceuticals (ADIL) price target decreased by 10.26% to 23.80 - MSN
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug - Sahm
Adial Pharmaceuticals completes AD04 demonstration batch production By Investing.com - Investing.com Australia
ADIL (Adial Pharmaceuticals Inc) reports wider than expected Q4 2025 loss, yet stock notches 2.53 percent gain today.Quick Ratio - UBND thành phố Hải Phòng
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):